Lifestyle Modification as the Primary Treatment of NASH

Clinics in Liver Disease

Volumn 13, Issue 4, 2009, Pages 649-665

  Neuschwander Tetri, Brent A ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Exercise; High fructose corn syrup; Insulin resistance; Lipotoxicity; Obesity; Trans fatty acids

Indexed keywords

CERAMIDE DERIVATIVE; DIACYLGLYCEROL; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDYLCHOLINE; PHOSPHATIDIC ACID; SWEETENING AGENT;

BODY MASS; CELL DAMAGE; EATING HABIT; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; KINESIOTHERAPY; LIFESTYLE MODIFICATION; LIPOLYSIS; MOTIVATION; MUSCLE FUNCTION; MUSCLE MITOCHONDRION; NONALCOHOLIC FATTY LIVER; OBESITY; PATIENT COUNSELING; PHYSICAL ACTIVITY; REVIEW; RISK FACTOR; WALKING; WEIGHT REDUCTION;

DIET, FAT-RESTRICTED; EXERCISE; FATTY LIVER; FOOD HABITS; HUMANS; LIFE STYLE; MOTIVATION; PATIENT COMPLIANCE; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 70349765667     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2009.07.006     Document Type: Review

References (97)

1. Lee Y., Hirose H., Ohneda M., et al. Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships. Proc Natl Acad Sci U S A 91 23 (1994) 10878-10882
2. Cusi K. Nonalcoholic fatty liver disease in type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 16 2 (2009) 141-149
3. Han M.S., Park S.Y., Shinzawa K., et al. Lysophosphatidylcholine as a death effector in the lipoapoptosis of hepatocytes. J Lipid Res 49 1 (2008) 84-97
4. Day C.P., and James O.F. Steatohepatitis: a tale of two "hits". Gastroenterology 114 4 (1998) 842-845
5. Bradbury M.W., and Berk P.D. Lipid metabolism in hepatic steatosis. Clin Liver Dis 8 3 (2004) 639-671
6. Yamaguchi K., Yang L., McCall S., et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 45 6 (2007) 1366-1374
7. Day C.P. From fat to inflammation. Gastroenterology 130 1 (2006) 207-210
8. Malhi H., and Gores G.J. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis 28 4 (2008) 360-369
9. Anderson N., and Borlak J. Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. Pharmacol Rev 60 3 (2008) 311-357
10. Schenk S., Saberi M., and Olefsky J.M. Insulin sensitivity: modulation by nutrients and inflammation. J Clin Invest 118 9 (2008) 2992-3002
11. Day C.P., and James O.F. Hepatic steatosis: innocent bystander or guilty party?. Hepatology 27 6 (1998) 1463-1466
12. Sanyal A.J., Campbell-Sargent C., Mirshahi F., et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120 5 (2001) 1183-1192
13. Berk P.D. Regulatable fatty acid transport mechanisms are central to the pathophysiology of obesity, fatty liver, and metabolic syndrome. Hepatology 48 5 (2008) 1362-1376
14. 2-terminal kinase pathway. Diabetes 56 7 (2007) 1865-1871
15. Perseghin G., Lattuada G., De Cobelli F., et al. Habitual physical activity is associated with intrahepatic fat content in humans. Diabetes Care 30 3 (2007) 683-688
16. Belcher G., and Schernthaner G. Changes in liver tests during 1-year treatment of patients with type 2 diabetes with pioglitazone, metformin or gliclazide. Diabet Med 22 8 (2005) 973-979
17. Loomba R., Lutchman G., Kleiner D.E., et al. Clinical trial: pilot study of metformin for the treatment of nonalcoholic steatohepatitis. Aliment Pharmacol Ther 29 (2008) 172-182
18. Teranishi T., Ohara T., Maeda K., et al. Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus. Metabolism 56 10 (2007) 1418-1424
19. Nair S., Diehl A.M., Wiseman M., et al. Metformin in the treatment of nonalcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther 20 1 (2004) 23-28
20. Schwimmer J.B., Middleton M.S., Deutsch R., et al. A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric nonalcoholic steatohepatitis. Aliment Pharmacol Ther 21 7 (2005) 871-879
21. Marchesini G., Brizi M., Bianchi G., et al. Metformin in nonalcoholic steatohepatitis (letter). Lancet 358 9285 (2001) 893-894
22. Bugianesi E., Gentilcore E., Manini R., et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 100 5 (2005) 1082-1090
23. Fukukura Y., Fujiyoshi F., Inoue H., et al. Focal fatty infiltration in the posterior aspect of hepatic segment IV: relationship to pancreaticoduodenal venous drainage. Am J Gastroenterol 95 12 (2000) 3590-3595
24. Atwell T.D., Lloyd R.V., Nagorney D.M., et al. Peritumoral steatosis associated with insulinomas: appearance at imaging. Abdom Imaging 33 5 (2008) 571-574
25. Fregeville A., Couvelard A., Paradis V., et al. Metastatic insulinoma and glucagonoma from the pancreas responsible for specific peritumoral patterns of hepatic steatosis secondary to local effects of insulin and glucagon on hepatocytes. Gastroenterology 129 4 (2005) 1150 365
26. Jolliet P., Leverve X., and Pichard C. Acute hepatic steatosis complicating massive insulin overdose and excessive glucose administration. Intensive Care Med 27 1 (2001) 313-316
27. Krasnoff J.B., Painter P.L., Wallace J.P., et al. Health-related fitness and physical activity in patients with nonalcoholic fatty liver disease. Hepatology 47 4 (2008) 1158-1166
28. Tamura Y., Tanaka Y., Sato F., et al. Effects of diet and exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 90 6 (2005) 3191-3196
29. Black S.E., Mitchell E., Freedson P.S., et al. Improved insulin action following short-term exercise training: role of energy and carbohydrate balance. J Appl Phys 99 6 (2005) 2285-2293
30. Gauthier M.S., Couturier K., Latour J.G., et al. Concurrent exercise prevents high-fat-diet-induced macrovesicular hepatic steatosis. J Appl Phys 94 6 (2003) 2127-2134
31. Nielsen S., Guo Z., Johnson C.M., et al. Splanchnic lipolysis in human obesity. J Clin Invest 113 11 (2004) 1582-1588
32. Church T.S., Kuk J.L., Ross R., et al. Association of cardiorespiratory fitness, body mass index, and waist circumference to nonalcoholic fatty liver disease. Gastroenterology 130 7 (2006) 2023-2030
33. Zelber-Sagi S., Nitzan-Kaluski D., Goldsmith R., et al. Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study. Hepatology 48 6 (2008) 1791-1798
34. Caldwell S.H., Chang C.Y., Nakamoto R.K., et al. Mitochondria in nonalcoholic fatty liver disease. Clin Liver Dis 8 3 (2004) 595-617
35. Pessayre D. Role of mitochondria in nonalcoholic fatty liver disease. J Gastroenterol Hepatol 22 Suppl 1 (2007) S20-S27
36. Petersen K.F., Dufour S., Befroy D., et al. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 350 (2004) 664-671
37. Petersen K.F., Dufour S., and Shulman G.I. Decreased insulin-stimulated ATP synthesis and phosphate transport in muscle of insulin-resistant offspring of type 2 diabetic parents. PLoS Med 2 9 (2005) e233
38. Holloway G.P., Bonen A., and Spriet L.L. Regulation of skeletal muscle mitochondrial fatty acid metabolism in lean and obese individuals. Am J Clin Nutr 89 1 (2009) 455S-462S
39. De Filippis E., Alvarez G., Berria R., et al. Insulin-resistant muscle is exercise resistant: evidence for reduced response of nuclear-encoded mitochondrial genes to exercise. Am J Physiol Endocrinol Metab 294 3 (2008) E607-E614
40. Stefan N., Thamer C., Staiger H., et al. Genetic variations in PPARD and PPARGC1A determine mitochondrial function and change in aerobic physical fitness and insulin sensitivity during lifestyle intervention. J Clin Endocrinol Metab 92 5 (2007) 1827-1833
41. Lowell B.B., and Shulman G.I. Mitochondrial dysfunction and type 2 diabetes. Science 307 5708 (2005) 384-387
42. Freeman H.C., Hugill A., Dear N.T., et al. Deletion of nicotinamide nucleotide transhydrogenase: a new quantitative trait locus accounting for glucose intolerance in C57BL/6J mice. Diabetes 55 7 (2006) 2153-2156
43. Toye A.A., Lippiat J.D., Proks P., et al. A genetic and physiological study of impaired glucose homeostasis control in C57BL/6J mice. Diabetologia 48 4 (2005) 675-686
44. Dengel D.R., Pratley R.E., Hagberg J.M., et al. Distinct effects of aerobic exercise training and weight loss on glucose homeostasis in obese sedentary men. J Appl Phys 81 1 (1996) 318-325
45. Orchard T.J., Temprosa M., Goldberg R., et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 142 8 (2005) 611-619
46. Lindström J., Ilanne-Parikka P., Peltonen M., et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 368 9548 (2006) 1673-1679
47. Schenk S., and Horowitz J.F. Acute exercise increases triglyceride synthesis in skeletal muscle and prevents fatty acid-induced insulin resistance. J Clin Invest 117 6 (2007) 1690-1698
48. Tiikkainen M., Bergholm R., Vehkavaara S., et al. Effects of identical weight loss on body composition and features of insulin resistance in obese women with high and low liver fat content. Diabetes 52 3 (2003) 701-707
49. Suzuki A., Lindor K., St Saver J., et al. Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. J Hepatol 43 6 (2005) 1060-1066
50. Harrison S.A., Fecht W., Brunt E.M., et al. Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology 49 1 (2009) 80-86
51. Marchesini G., Natale S., Manini R., et al. Review article: the treatment of fatty liver disease associated with the metabolic syndrome. Aliment Pharmacol Ther 22 Suppl 2 (2005) 37-39
52. Kashi M.R., Torres D.M., and Harrison S.A. Current and emerging therapies in nonalcoholic fatty liver disease. Semin Liver Dis 28 4 (2008) 396-406
53. Rafiq N., and Younossi Z.M. Effects of weight loss on nonalcoholic fatty liver disease. Semin Liver Dis 28 4 (2008) 427-433
54. Nobili V., Manco M., Devito R., et al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology 48 1 (2008) 119-128
55. Luyckx F.H., Desaive C., Thiry A., et al. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord 22 3 (1998) 222-226
56. Kral J.G., Thung S.N., Biron S., et al. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery 135 1 (2004) 48-58
57. Rozental P., Biava C., Spencer H., et al. Liver morphology and function tests in obesity and during total starvation. Am J Dig Dis 12 (1967) 198-208
58. Capron J.P., Delamarre J., Dupas J.L., et al. Fasting in obesity: another cause of liver injury with alcoholic hyaline?. Dig Dis Sci 27 (1982) 265-268
59. Verna E.C., and Berk P.D. Role of fatty acids in the pathogenesis of obesity and fatty liver: impact of bariatric surgery. Semin Liver Dis 28 4 (2008) 407-426
60. Hu F.B., Li T.Y., Colditz G.A., et al. Television watching and other sedentary behaviors in relation to risk of obesity and type 2 diabetes mellitus in women. JAMA 289 14 (2003) 1785-1791
61. Schäfer S., Kantartzis K., Machann J., et al. Lifestyle intervention in individuals with normal versus impaired glucose tolerance. Eur J Clin Invest 37 7 (2007) 535-543
62. Elliott S.S., Keim N.L., Stern J.S., et al. Fructose, weight gain, and the insulin resistance syndrome. Am J Clin Nutr 76 5 (2002) 911-922
63. Bray G.A., Nielsen S.J., and Popkin B.M. Consumption of high-fructose corn syrup in beverages may play a role in the epidemic of obesity. Am J Clin Nutr 79 4 (2004) 537-543
64. Ouyang X., Cirillo P., Sautin Y., et al. Fructose consumption as a risk factor for nonalcoholic fatty liver disease. J Hepatol 48 6 (2008) 993-999
65. Henry R.R., Crapo P.A., and Thorburn A.W. Current issues in fructose metabolism. Annu Rev Nutr 11 (1991) 21-39
66. Terrier F., Vock P., Cotting J., et al. Effect of intravenous fructose on the P-31 MR spectrum of the liver: dose response in healthy volunteers. Radiology 171 2 (1989) 557-563
67. Teff K.L., Elliott S.S., Tschop M., et al. Dietary fructose reduces circulating insulin and leptin, attenuates postprandial suppression of ghrelin, and increases triglycerides in women. J Clin Endocrinol Metab 89 6 (2004) 2963-2972
68. Shapiro A., Mu W., Roncal C., et al. Fructose-induced leptin resistance exacerbates weight gain in response to subsequent high-fat feeding. Am J Physiol Regul Integr Comp Physiol 295 5 (2008) R1370-R1375
69. Mossoba M.M., Kramer J.K.G., Delmonte P., et al. Official methods for the determination of Trans fat (2003), AOCS Press, Champaign (IL)
70. Ibrahim A., Natrajan S., and Ghafoorunissa R. Dietary trans-fatty acids alter adipocyte plasma membrane fatty acid composition and insulin sensitivity in rats. Metabolism 54 2 (2005) 240-246
71. Katz A.M. Should trans fatty acids be viewed as membrane-active drugs?. Atheroscler Suppl 7 2 (2006) 41-42
72. Mozaffarian D., Katan M.B., Ascherio A., et al. Trans fatty acids and cardiovascular disease. N Engl J Med 354 15 (2006) 1601-1613
73. Kechagias S., Ernersson Å D.O., et al. Fast-food-based hyper-alimentation can induce rapid and profound elevation of serum alanine aminotransferase in healthy subjects. Gut 57 5 (2008) 649-654
74. Stender S., Dyerberg J., and Astrup A. High levels of industrially produced trans fat in popular fast foods. N Engl J Med 354 15 (2006) 1650-1652
75. Araya J., Rodrigo R., Videla L.A., et al. Increase in long-chain polyunsaturated fatty acid n - 6/n - 3 ratio in relation to hepatic steatosis in patients with nonalcoholic fatty liver disease. Clin Sci (Lond) 106 6 (2004) 635-643
76. Tetri L.H., Basaranoglu M., Brunt E.M., et al. Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol 295 5 (2008) G987-G995
77. Satchithanandam S., Oles C.J., Spease C.J., et al. Trans, saturated, and unsaturated fat in foods in the United States prior to mandatory trans-fat labeling. Lipids 39 1 (2004) 11-18
78. Eckel R.H., Borra S., Lichtenstein A.H., et al. Understanding the complexity of trans fatty acid reduction in the American diet: American Heart Association Trans Fat Conference 2006: report of the Trans Fat Conference Planning Group. Circulation 115 16 (2007) 2231-2246
79. Albers M.J., Harnack L.J., Steffen L.M., et al. 2006 marketplace survey of trans-fatty acid content of margarines and butters, cookies and snack cakes, and savory snacks. J Am Diet Assoc 108 2 (2008) 367-370
80. Willett W.C., and Mozaffarian D. Trans fats in cardiac and diabetes risk: an overview. Curr Cardiovasc Risk Rep 1 (2007) 16-23
81. Eckel R.H., Kris-Etherton P., Lichtenstein A.H., et al. Americans' awareness, knowledge, and behaviors regarding fats: 2006-2007. J Am Diet Assoc 109 2 (2009) 288-296
82. Borra S., Kris-Etherton P.M., Dausch J.G., et al. An update of trans-fat reduction in the American diet. J Am Diet Assoc 107 12 (2007) 2048-2050
83. Jones N.L., and Killian K.J. Exercise limitation in health and disease. N Engl J Med 343 9 (2000) 632-641
84. Bouneva I., and Kirby D.F. Management of nonalcoholic fatty liver disease: weight control. Clin Liver Dis 8 3 (2004) 693-713
85. Eden K.B., Orleans C.T., Mulrow C.D., et al. Does counseling by clinicians improve physical activity? A summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 137 3 (2002) 208-215
86. Sacks F.M., Bray G.A., Carey V.J., et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med 360 9 (2009) 859-873
87. Kirk E., Reeds D.N., Finck B.N., et al. Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. Gastroenterology 136 5 (2009) 1552-1560
88. Bonow R.O., and Eckel R.H. Diet, obesity, and cardiovascular risk. N Engl J Med 348 (2003) 2057-2058
89. Harrison S.A., and Day C.P. Benefits of lifestyle modification in NAFLD. Gut 56 12 (2007) 1760-1769
90. Palmer M., and Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 99 5 (1990) 1408-1413
91. Ueno T., Sugawara H., Sujaku K., et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 27 1 (1997) 103-107
92. Kugelmas M., Hill D.B., Vivian B., et al. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 38 (2003) 413-419
93. Hickman I.J., Jonsson J.R., Prins J.B., et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 53 3 (2004) 413-419
94. Vajro P., Mandato C., Franzese A., et al. Vitamin E treatment in pediatric obesity-related liver disease: a randomized study. J Pediatr Gastroenterol Nutr 38 1 (2004) 48-55
95. Huang M.A., Greenson J.K., Chao C., et al. One-year intense nutritional counseling results in histological improvement in patients with nonalcoholic steatohepatitis: a pilot study. Am J Gastroenterol 100 5 (2005) 1072-1081
96. Wang C.-L., Liang L., Fu J.-F., et al. Effect of lifestyle intervention on nonalcoholic fatty liver disease in Chinese obese children. World J Gastroenterol 14 10 (2008) 1598-1602
97. Nobili V., Manco M., Devito R., et al. Effect of vitamin E on aminotransferase levels and insulin resistance in children with nonalcoholic fatty liver disease. Aliment Pharmacol Ther 24 11-12 (2006) 1553-1561